Viking Therapeutics Inc (NASDAQ:VKTX) Sellers Reduced Their Shorts By 14.3% As Of May 3, 2018

May 3, 2018 - By Mark Williams

Viking Therapeutics, Inc. (NASDAQ:VKTX) Corporate Logo

Change of 14.3% for Viking Therapeutics Inc (NASDAQ:VKTX)’s shorted shares was recorded. FINRA announced shorted shares of VKTX’s total 2.42M shares. Previously was reported down change of 14.3% from 2.82 million shares. With Average volume 845,000, VKTX’s former position will take 3 days to restore. Float short on Viking Therapeutics Inc is 13.11%.

VKTX is reaching $4.13 during the last trading session, after decreased 2.82%.Viking Therapeutics, Inc. has volume of 416,121 shares. Since May 3, 2017 VKTX has risen 240.16% and is uptrending. VKTX outperformed the S&P 500 by 228.61%.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders.The firm is worth $210.35 million. The Company’s lead clinical program is VK5211, an orally available drug candidate, which is in a phase II clinical trials for acute rehabilitation following non-elective hip fracture surgery.Currently it has negative earnings. The firm also develops VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease, as well as for the orphan indication glycogen storage disease type Ia; and VK0214 for the treatment of orphan indication X-linked adrenoleukodystrophy, a rare X-linked, inherited neurological disorder.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Ratings Coverage

A total of 3 analysts rate Viking Therapeutics (NASDAQ:VKTX) as follows: 3 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:VKTX) has 6 ratings reports on May 3, 2018 according to StockzIntelligence. On Monday, March 26 the rating was reinitiated by H.C. Wainwright with “Buy”. The stock rating was maintained by Roth Capital with “Buy” on Thursday, March 8. On Wednesday, November 29 the firm has “Buy” rating given by Roth Capital. On Friday, November 10 the stock of Viking Therapeutics, Inc. (NASDAQ:VKTX) earned “Buy” rating by H.C. Wainwright. On Tuesday, November 21 the stock of Viking Therapeutics, Inc. (NASDAQ:VKTX) earned “Buy” rating by Roth Capital.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.